Education
About Us
Working with TipRanks
Follow Us
Evolva Holding Sa (CH:EVE)
:EVE
Top Page
Evolva Holding
(OTC:EVE)
54Neutral
Evolva Holding (EVE) vs. S&P 500 (SPY)
Market Cap
CHF8.76M
Dividend YieldN/A
Average Volume (3M)16.10K
Price to Earnings (P/E)7.6
Beta (1Y)0.21
Revenue Growth-100.00%
EPS GrowthN/A
CountryCH
Employees49
SectorHealthcare
Sector Strength64
IndustryBiotechnology
Share Statistics
EPS (TTM)0.14
Shares Outstanding7,230,626
10 Day Avg. Volume12,994
30 Day Avg. Volume16,104
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Evolva Holding Business Overview & Revenue Model
Company DescriptionEvolva Holding (EVE) is a Swiss-based biotechnology company focused on the research, development, and commercialization of innovative ingredients derived from nature. The company leverages advanced biosynthesis technology to produce high-value compounds for use in various sectors, including food, cosmetics, and personal care. Evolva's core products are sustainable and environmentally friendly alternatives to traditional ingredients, offering enhanced performance and value.
How the Company Makes MoneyEvolva makes money primarily through the sale of its biosynthesized ingredients to businesses in the food, beverage, flavor, fragrance, and personal care industries. The company operates on a B2B model, partnering with major companies to incorporate its ingredients into their products. Revenue streams include direct sales of ingredients, licensing agreements, and long-term partnerships with key industry players. Evolva benefits from its proprietary biotechnology platform, which allows for efficient, scalable production of high-quality, sustainable compounds. Additionally, the company may earn income through research and development collaborations and grants, contributing to its overall revenue.
Evolva Holding Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 9.44M | 15.54M | 9.88M | 7.54M | 11.60M | Gross Profit |
| -2.58M | -8.89M | -15.57M | -9.91M | -2.46M | EBIT |
| -92.25M | -23.36M | -31.90M | -21.30M | -20.13M | EBITDA |
| -98.36M | -34.52M | -31.82M | -20.60M | -13.18M | Net Income Common Stockholders |
| -105.23M | -43.37M | -41.27M | -29.87M | -21.64M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 5.84M | 5.14M | 11.00M | 19.67M | 39.92M | Total Assets |
| 9.83M | 131.01M | 156.17M | 166.89M | 192.08M | Total Debt |
| 0.00 | 15.06M | 10.84M | 9.02M | 6.13M | Net Debt |
| -5.84M | 9.91M | -161.30K | -10.65M | -33.79M | Total Liabilities |
| 4.28M | 24.77M | 24.40M | 21.80M | 19.52M | Stockholders Equity |
| 5.55M | 106.24M | 131.77M | 145.09M | 172.56M |
| Cash Flow | Free Cash Flow | |||
| -9.72M | -21.13M | -33.57M | -28.97M | -19.53M | Operating Cash Flow |
| -9.25M | -18.88M | -29.79M | -23.36M | -14.16M | Investing Cash Flow |
| 15.95M | -1.76M | -4.64M | -5.60M | -5.33M | Financing Cash Flow |
| -5.97M | 14.77M | 25.72M | 8.86M | -920.00K |
Evolva Holding Technical Analysis
Positive
1.18
Price Trends
1.22
Negative
1.10
Positive
0.99
Positive
Market Momentum
>-0.01
Negative
50.35
Neutral
60.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:EVE, the sentiment is Positive. The current price of 1.18 is above the 20-day moving average (MA) of 1.18, below the 50-day MA of 1.22, and above the 200-day MA of 0.99, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.35 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:EVE.
Evolva Holding Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Performance Comparison
CH:EVE
Evolva Holding
1.18
0.17
16.83%
CH:MOLN
Molecular Partners AG
3.39
0.19
5.94%
CH:RLF
RELIEF THERAPEUTICS Holding
2.39
1.13
90.80%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.